Both the Wegovy and Zepbound labels state that weight loss offers no benefit to a pregnant patient and may cause fetal harm, and they ask for the medicine to be stopped when a pregnancy is recognized. Because semaglutide lasts so long in the body, the Wegovy label advises stopping it at least 2 months, about 8 weeks, before a planned pregnancy.1,2
What is known about the risk
The evidence in people is thin. The Wegovy label says pharmacovigilance and trial data in pregnant patients are insufficient to establish a drug-associated risk of major birth defects, miscarriage or other adverse outcomes; the Zepbound label says the same of tirzepatide. Both note that animal reproduction studies suggest possible risks to the fetus.1,2 Both makers run pregnancy exposure registries that collect outcomes from women who took the drug while pregnant, and patients and doctors are encouraged to report.1,2
One exception is written into the Wegovy label. For a scarring form of fatty liver disease, MASH with advanced fibrosis, the condition itself carries risks in pregnancy, and the label allows use only if the potential benefit justifies the potential risk to the fetus.1
Planning a pregnancy
The 2-month gap for Wegovy follows from its half-life of about 1 week: the Ozempic label says semaglutide stays in the circulation for about 5 weeks after the last dose.1,3 Tirzepatide has a shorter half-life, about 5 days, and the Zepbound label asks for it to be stopped when a pregnancy is recognized.2 The label for the semaglutide tablets, Rybelsus and Ozempic tablets, gives the same advice: stop at least 2 months before a planned pregnancy, because of the long washout period.4
A 2025 review of the use of these medicines before conception describes why the question is growing. Obesity is rising among women of reproductive age and contributes to reduced fertility, guidelines encourage weight loss before conception, and unplanned pregnancies remain common, so early exposure is becoming more likely.5 The review also notes growing interest in using these medicines to support weight loss and fertility before conception, and it focuses on safety in the preconception period and on accidental exposure in early pregnancy. Several of its authors report fees from the makers.5
If a pregnancy starts on the medicine
The labels give the steps. When a pregnancy is recognized, the patient is told of the possible risk to the fetus and the drug is stopped if it is being used for weight. Both makers ask for exposed pregnancies to be reported to their registries: Novo Nordisk at 1-877-390-2760 for Wegovy, and Eli Lilly at 1-800-545-5979 for Zepbound.1,2 Telling the obstetric team the date of the last dose helps them judge how much of the drug may still be in the body.
Birth control pills
Tirzepatide can make birth control pills less effective. The Zepbound and Mounjaro labels advise people on oral contraceptives to switch to a non-oral method, or add a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase. The slower stomach emptying it causes is largest after the first dose and shrinks over time.2,6 Our page on Zepbound and birth control puts those weeks on a calendar.
Breastfeeding
- Wegovy tablets: breastfeeding is not recommended, because SNAC, the absorption enhancer in the tablet, and its products pass into milk and may build up in infants. Semaglutide itself was below the measurable level in milk.1
- Wegovy injection: there are no data on semaglutide in milk; the injection contains no SNAC. The label asks for the benefits of breastfeeding to be weighed against the mother's need for the drug.1
- Zepbound: in a single-dose study, tirzepatide in breast milk was undetectable or low. There are no data on effects on the infant or on milk production.2
Sources
- WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 8.1, 8.2 and 8.3. accessdata.fda.gov
- ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 8.1, 8.2, 8.3 and 12.3. accessdata.fda.gov
- OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; section 12.3. accessdata.fda.gov
- RYBELSUS and OZEMPIC (semaglutide) tablets prescribing information. Novo Nordisk; DailyMed, version 14, published August 19, 2026; sections 8.1 and 8.3. dailymed.nlm.nih.gov
- Koceva A, Jensterle M, et al. Preconception use of GLP-1 and GLP-1/GIP receptor agonists for obesity treatment. Best Pract Res Clin Endocrinol Metab 2025;39:102038. doi:10.1016/j.beem.2025.102038
- MOUNJARO (tirzepatide) prescribing information, NDA 215866/S-052, revised April 2026. U.S. Food and Drug Administration; section 8.3. accessdata.fda.gov
Related analyses
Zepbound and birth control pills: the 4-week rule, with your dates
How long does Zepbound stay in your system? The level, day by day
When to take your GLP-1 shot: time of day, changing the day and time zones
How to take the Wegovy pill: the water, the 30-minute wait and the dose steps
Log your last dose and your cycle in one place, so planning dates are easy to work out.
Open Dose Insider